{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematopoietic+Stem+Cell+Transplantations&page=22", "query": { "condition": "Hematopoietic Stem Cell Transplantations", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 1070, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematopoietic+Stem+Cell+Transplantations&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematopoietic+Stem+Cell+Transplantations&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T06:06:13.075Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00051311", "title": "Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Stem cell transplantation", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 62, "start_date": "2003-01-03", "completion_date": "2014-09-25", "has_results": true, "last_update_posted_date": "2021-09-09", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00051311" }, { "nct_id": "NCT03394365", "title": "A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)", "Solid Organ Transplant Complications", "Lymphoproliferative Disorders", "Allogeneic Hematopoietic Cell Transplant", "Stem Cell Transplant Complications" ], "interventions": [ { "name": "tabelecleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 115, "start_date": "2017-12-29", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 40, "location_summary": "Duarte, California • La Jolla, California • Loma Linda, California + 28 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03394365" }, { "nct_id": "NCT06938867", "title": "Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "E Coli Infections", "Allogenic Transplant Patients" ], "interventions": [ { "name": "SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli", "type": "BIOLOGICAL" }, { "name": "Placebo 10 mL", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SNIPR Biome Aps.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2024-12-04", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 10, "location_summary": "Duarte, California • San Francisco, California • Baltimore, Maryland + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06938867" }, { "nct_id": "NCT01605032", "title": "Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 19, "start_date": "2012-02", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 4, "location_summary": "New Brunswick, New Jersey • New York, New York • The Bronx, New York", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01605032" }, { "nct_id": "NCT06155500", "title": "Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "OTQ923", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 4, "start_date": "2024-04-16", "completion_date": "2039-01-11", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 3, "location_summary": "Chicago, Illinois • New York, New York • Memphis, Tennessee", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06155500" }, { "nct_id": "NCT04047628", "title": "Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis", "Relapsing Remitting Multiple Sclerosis", "Secondary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Best Available Therapy (BAT)", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 156, "start_date": "2020-08-17", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 23, "location_summary": "Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047628" }, { "nct_id": "NCT05194397", "title": "Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoblastic Leukemia", "Cancer Survivors", "Aplastic Anemia", "Myelodysplastic Syndromes", "Myeloid Leukemia" ], "interventions": [ { "name": "Nicotinamide Riboside", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" }, { "name": "Exercise Intervention", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "10 Years to 30 Years" }, "enrollment_count": 80, "start_date": "2023-02-23", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 3, "location_summary": "Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05194397" }, { "nct_id": "NCT05722210", "title": "Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematopoietic Stem Cell Transplant" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "3 Years to 90 Years" }, "enrollment_count": 500, "start_date": "2026-10-19", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05722210" }, { "nct_id": "NCT06059391", "title": "CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid System Neoplasm", "Hodgkin Lymphoma", "Myelodysplastic Syndrome", "Myelofibrosis", "Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Granulocyte Colony-Stimulating Factor", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation Conditioning Regimen", "type": "DRUG" }, { "name": "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine", "type": "BIOLOGICAL" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Stem Cell Mobilization Therapy", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 216, "start_date": "2024-07-12", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 3, "location_summary": "Duarte, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06059391" }, { "nct_id": "NCT00350818", "title": "Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome", "Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2005-10", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-10-15T06:06:13.075Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350818" } ] }